Our Team

Ed Seguine leads Target RWE as its Chief Executive Officer, driving the company's initiative to build robust longitudinal clinical evidence. His vision focuses on bridging the critical intersection of clinical research and clinical care, transforming how evidence is generated and utilized.

A seasoned leader with over two decades of experience, Ed has a proven track record in commercializing novel technologies and business models within the healthcare and pharmaceutical sectors. Prior to Target RWE, he successfully led a company to achieve record-setting business during a period of market volatility, revitalizing its commercial leadership and engineering focus, all while stabilizing financials. Notably, he founded Clinical Ink, pioneering the industry's first Electronic Source Record (eSource) data capture platform for clinical trials, which significantly streamlined data capture and remote monitoring.

Known for his resourceful and humble leadership, Ed is an expert in navigating critical inflection points, including venture capital and M&A transactions, crisis turnarounds, and strategic partnerships. His career is marked by a pattern of building from scratch and achieving industry "firsts," reflecting deep expertise in applying technology and data to solve complex business process problems in healthcare and pharma.

Michael W. Fried, MD, FAASLD is Chief Medical Officer and Co-Founder of Target RWE. He is also Professor of Medicine at the University of North Carolina at Chapel Hill and Past-President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried trained at the State University of New York at Syracuse and the National Institutes of Health, Bethesda, MD, which provided him with the foundation for his 30 years of experience in clinical and translational research. Dr. Fried is co-author of 200+ publications in the field of liver disease and is currently co-chair of the NIH Hepatitis B Research Network. He is co-principal investigator of the HCV-TARGET network which was awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for hepatitis C.

Jennifer Christian, PharmD, PhD, FISPE is the Chief Scientific Officer at Target RWE where she provides scientific oversight and leadership that focuses on generating meaningful real world evidence for regulators, clinicians, patients, and payers. Throughout her 20+ year career, her research has focused on strengthening clinical effectiveness and safety evaluations of newly approved treatments through advanced epidemiology methods, examining treatment effect heterogeneity, and conducting patient centered analyses.

Prior to joining Target RWE, Jennifer was Vice President & General Manager of Medical & Scientific Services at IQVIA where she was instrumental in generating RWE through epidemiology and drug safety studies, pragmatic trials, external comparator studies, health outcomes research, systematic literature reviews, and surveys or chart abstractions.

Jennifer is a Fellow and VP of Finance for the International Society of Pharmacoepidemiology, a Fellow of the National Academy of Medicine, a member of the PCORI Clinical Trials Methods Advisory Panel, a co-founder of the RWE Alliance, and a member of the Duke Margolis RWE Methods Working Group. She is an adjunct faculty member within the Division of Clinical Epidemiology and Evaluative Sciences Research at Weill Cornell Medical College, and she holds a Doctorate in Pharmacy and an MPH in Epidemiology from UNC-Chapel Hill as well as a Doctorate in Epidemiology from Brown University.

Currently serving as CTO at Target RWE, Raheem Daya is a seasoned technology leader with over 25 years of experience in managing and transforming complex technical environments for diverse organizations, from startups to major industry players. He excels in building and leading high-performance technical teams and implementing innovative solutions that align technology with business objectives. Prior to this, he was with Amazon Web Services, where he led the development of groundbreaking prototypes using cutting-edge technologies including large-scale processing, machine learning, and generative AI for public sector clients in various domains including genomics, health care, and EdTech.

Before this, Raheem spent 12 years at McKesson in various roles. As VP of Technology at Macro Helix, he led a major technical transformation, reduced outages by 95%, and migrated platforms to Azure. His earlier roles at McKesson involved leading the way in the use of big data technologies and data science to improve business outcomes. He was awarded two McKesson Distinguished Technologist awards for his contributions in these areas.

Raheem holds a BS in Computer Science from Georgia State University and a Certificate of Readiness from Harvard Business School Online.

Steve Swanson is the Senior Vice President and Head of Business Development at Target RWE where he leads the company's commercial strategies, focusing on expanding commercial partnerships with health systems and life sciences research partners.

Prior to joining Target RWE, Steve served as Vice President of Life Sciences Partnerships at Flatiron Health. As a founding member of the San Francisco office, he established collaborations with leading life sciences companies, concentrating on oncology real-world evidence. Steve's earlier experience includes roles in early research at Regeneron Pharmaceuticals, global value and access consulting with IQVIA, and mentoring health tech startup leaders in San Francisco and New York City.

He holds a Master's degree in Biotechnology from Columbia University and a Bachelor's degree in Genetics and Technology Management from the University of California, Davis.

Matt brings more than 20 years of experience in working in the finance/accounting industry with positions in the pharmaceutical, CRO, software, and government sectors that included publicly traded and private equity-backed enterprises.

Prior to joining Target RWE, Matt spent more than 2 years as an Engagement Director for CliftonLarsonAllen where he provided technical accounting services and executed system implementations for clients in the banking and services industries. He completed his Bachelor of Accounting degree from DeSales University and received his Executive MBA from Drexel University’s LeBow College of Business.

Julie Mallory Crawford, MD is currently serving as Vice President of RWE and Strategic Partnerships for Target RWE Health Evidence Solutions. She has held multiple other roles at Target RWE, including Senior Director of Scientific & Medical Affairs, Director of Strategy, and Senior Manager of Medical Affairs. Prior to joining Target RWE, Julie was a Fellow at Hatteras Venture Partners, where she qualified deal flow, assessed early-stage healthcare related companies, and was a board observer.

Julie received her BA in English from Williams College, where she was an NCAA All-American on the women’s tennis team. She then received her MD from Columbia University Vagelos College of Physicians & Surgeons in New York City. She completed an internship in internal medicine and matched into the Ophthalmology residency at Columbia University before making the transition to industry.

Tara Bridgeman is the Sr. Director, Human Resources for Target RWE. Tara brings 20+ years of Human Resources experience to the company. Prior to joining Target RWE Health Evidence Solutions, Tara was the Vice President of Human Resources at Dude Solutions where she was responsible for leading the people, culture, and human resources operational initiatives. Prior to Dude Solutions, Tara additionally held numerous leadership roles at Blue Cross Blue Shield of NC where she was accountable and in charge of executing the talent and staffing strategies, building the employee relations function, and overseeing HR compliance.

Alan is a biostatistician and an epidemiologist who has spent the last 15 years developing and applying epidemiological and statistical methods for studies using real-world healthcare data. He has more than 200 publications in leading journals in medicine, biostatistics, and epidemiology. In 2021 Target RWE acquired his company NoviSci, Inc., a company that built and applied analytic software and visualization tools for RWE generation.

Currently, Alan is also a Professor in the Department of Population Health Sciences at Duke University, an Adjunct Professor at UNC Chapel Hill, and an Honorary Professor of Clinical Epidemiology at the University of Aarhus, Denmark. Previously Alan was on faculty at Harvard Medical School and was also a co-founder and chair of the scientific advisory board of RxAnte, Inc., a provider of widely used predictive analytics for decision support. Alan is a member of many scientific advisory groups, review panels, and editorial boards.